All In Biotech

Drug Trial Radar · NCT06261359

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

A Phase II, Randomized, Double-blind, Multi-center, Placebo-Controlled Study of the Efficacy and Safety of CEND-1 in Combination With Chemotherapy as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 19, 2024

Primary completion

Apr 2025

Study completion Oct 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • CEND-1Drug

    CEND-1 will be provided as concentrate for solution to be administered via IV injection.

  • GemcitabineDrug

    Gemcitabine will be provided as solution to be administered via IV infusion.

  • Nab paclitaxelDrug

    Nab-paclitaxel will be provided as solution to be administered via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Approximately 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese People's Liberation Army (PLA) General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.